Taysha Gene Therapies, Inc. (NASDAQ:TSHA) CFO Sells $28,932.12 in Stock
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) CFO Sells $28,932.12 in Stock
Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Get Rating) CFO Kamran Alam sold 7,476 shares of the firm's stock in a transaction on Thursday, August 18th. The shares were sold at an average price of $3.87, for a total value of $28,932.12. Following the sale, the chief financial officer now directly owns 290,645 shares of the company's stock, valued at $1,124,796.15. The transaction was disclosed in a document filed with the SEC, which is available through this link.
泰莎基因療法公司(納斯達克代碼：TSHA-GET評級)首席財務官卡姆蘭·阿拉姆在8月18日星期四的一筆交易中出售了該公司7,476股股票。這些股票的平均價格為3.87美元，總價值為28,932.12美元。出售後，首席財務官現在直接持有290,645股公司股票，價值1,124,796.15美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的，可以通過這個鏈接獲得。
Kamran Alam also recently made the following trade(s):
卡姆蘭·阿拉姆最近還進行了以下交易：
- On Monday, August 22nd, Kamran Alam sold 9,717 shares of Taysha Gene Therapies stock. The shares were sold at an average price of $3.50, for a total value of $34,009.50.
- 8月22日，星期一，卡姆蘭·阿拉姆出售了9,717股泰莎基因療法股票。這些股票的平均價格為3.50美元，總價值為34,009.50美元。
Taysha Gene Therapies Stock Performance
泰莎基因療法的股票表現
Shares of TSHA traded down $0.31 during mid-day trading on Monday, reaching $3.43. 69,277 shares of the company's stock were exchanged, compared to its average volume of 240,529. The business's fifty day simple moving average is $4.00 and its 200-day simple moving average is $4.77. Taysha Gene Therapies, Inc. has a 52-week low of $2.33 and a 52-week high of $21.90. The company has a debt-to-equity ratio of 1.15, a current ratio of 1.79 and a quick ratio of 1.79. The stock has a market capitalization of $140.95 million, a PE ratio of -0.71 and a beta of 0.99.
在週一午盤交易中，TSHA的股價下跌了0.31美元，達到3.43美元。該公司股票成交量為69,277股，而其平均成交量為240,529股。該業務的50日簡單移動均線切入位為4.00美元，200日簡單移動均線切入位為4.77美元。塔莎基因療法公司的股價為2.33美元，為52周低點，52周高點為21.90美元。該公司的債務權益比為1.15，流動比率為1.79，速動比率為1.79。該股市值為1.4095億美元，市盈率為-0.71，貝塔係數為0.99。
Analyst Ratings Changes
分析師評級發生變化
Institutional Trading of Taysha Gene Therapies
塔莎基因療法的制度性交易
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Northern Trust Corp raised its position in shares of Taysha Gene Therapies by 1.4% during the 4th quarter. Northern Trust Corp now owns 214,970 shares of the company's stock valued at $2,504,000 after acquiring an additional 3,042 shares in the last quarter. Virtus ETF Advisers LLC lifted its stake in Taysha Gene Therapies by 39.3% in the 4th quarter. Virtus ETF Advisers LLC now owns 11,519 shares of the company's stock worth $134,000 after acquiring an additional 3,251 shares in the last quarter. Swiss National Bank increased its position in Taysha Gene Therapies by 9.3% in the 1st quarter. Swiss National Bank now owns 41,000 shares of the company's stock worth $267,000 after purchasing an additional 3,500 shares during the last quarter. Occudo Quantitative Strategies LP grew its holdings in Taysha Gene Therapies by 17.9% in the 2nd quarter. Occudo Quantitative Strategies LP now owns 31,030 shares of the company's stock valued at $115,000 after buying an additional 4,702 shares during the last quarter. Finally, Quantum Private Wealth LLC lifted its position in shares of Taysha Gene Therapies by 3.8% in the 2nd quarter. Quantum Private Wealth LLC now owns 157,774 shares of the company's stock worth $586,000 after acquiring an additional 5,800 shares during the period. Hedge funds and other institutional investors own 46.05% of the company's stock.
幾家對衝基金和其他機構投資者最近增持或減持了該業務的股份。北方信託公司在第四季度將其在塔莎基因療法公司的股票頭寸提高了1.4%。Northern Trust Corp目前持有214,970股該公司股票，價值2,504,000美元，此前該公司在上個季度又收購了3,042股。Virtus ETF Advisers LLC在第四季度將其在塔莎基因療法公司的持股比例提高了39.3%。Virtus ETF Advisers LLC現在擁有11,519股該公司的股票，價值13.4萬美元，上個季度又購買了3,251股。瑞士國家銀行第一季度增持泰莎基因療法9.3%的頭寸。瑞士國家銀行在上個季度又購買了3,500股，現在持有41,000股該公司股票，價值267,000美元。Occudo Quantity Strategy LP在第二季度增持了17.9%的泰莎基因療法。Occudo Quantity Strategy LP在上個季度又購買了4,702股後，現在擁有31,030股該公司股票，價值11.5萬美元。最後，量子私人財富有限責任公司在第二季度將其在塔莎基因療法公司的股票頭寸提高了3.8%。量子私人財富有限責任公司在此期間額外收購了5800股，現在擁有157,774股該公司的股票，價值58.6萬美元。對衝基金和其他機構投資者持有該公司46.05%的股份。
About Taysha Gene Therapies
關於塔莎基因療法
(Get Rating)
(獲取評級)
Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis.
泰莎基因療法公司是一家基因治療公司，專注於開發基於腺相關病毒的基因療法並將其商業化，用於治療中樞神經系統單基因疾病。它主要開發用於治療巨大軸索性神經病的TSHA-120；用於治療Rett綜合徵的TSHA-102；用於治療CLN1疾病的TSHA-121；用於治療CLN1疾病的TSHA-118；用於治療SLC13A5缺乏症的TSHA-105；以及用於治療GM2神經節苷脂缺乏的TSHA-101。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on Taysha Gene Therapies (TSHA)
- Oil Services: Who Will Lead The Rebound?
- Analog Devices Reveals Semiconductor Demand Problems
- Three Ways To Find Hot Stocks In A Tepid Market
- Here are the Multiple Stages of a Bear Market
- 3 August Earnings Reports With 'Wow' Potential
- 免費獲取StockNews.com關於塔莎基因療法的研究報告(TSHA)
- 石油服務：誰將引領本輪反彈？
- ADI公司揭露半導體需求問題
- 在不温不火的市場中尋找熱門股票的三種方法
- 以下是熊市的多個階段
- 3份潛在的8月份收益報告
Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.
接受《泰莎基因療法日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊，接收最新新聞和分析師對塔莎基因療法和相關公司評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。